Raquel González|Meghna Desai|Eusébio Macete|Peter Ouma|Mwaka A. Kakolwa|Salim Abdulla|John J. Aponte|Helder Bulo|Abdunoor M. Kabanywanyi|Abraham Katana|Sonia Maculuve|Alfredo Mayor|Arsénio Nhacolo|Kephas Otieno|Golbahar Pahlavan|Maria Rosario|Esperança Sevene|Laurence Slutsker|Anifa Valá|John Williamsom|Clara Menéndez
Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial
Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Centers for Disease Control and Prevention|Kenya Medical Research Institute|Division of Parasitic Diseases and Malaria|Center for Global Health|Manhiça Health Research Centre|Kenya Medical Research Institute|Centers for Disease Control and Prevention|Ifakara Health Institute|Ifakara Health Institute|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Manhiça Health Research Centre|Ifakara Health Institute|Kenya Medical Research Institute|Centers for Disease Control and Prevention|Manhiça Health Research Centre|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Manhiça Health Research Centre|Kenya Medical Research Institute|Centers for Disease Control and Prevention|Barcelona Institute for Global Health|Universitat de Barcelona|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Manhiça Health Research Centre|Centers for Disease Control and Prevention|Division of Parasitic Diseases and Malaria|Center for Global Health|Manhiça Health Research Centre|Centers for Disease Control and Prevention|Kenya Medical Research Institute|Division of Parasitic Diseases and Malaria|Center for Global Health|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre
intermittent preventive treatment pregnancy iptp sulfadoxinepyrimethamine sp recommended malaria prevention hivnegative pregnant women contraindicated hivinfected women taking daily cotrimoxazole prophylaxis ctxp potential added risk adverse effects associated taking two antifolate drugs simultaneously studied safety efficacy mefloquine mq women receiving ctxp longlasting insecticide treated nets llitnsa total 1071 hivinfected women kenya mozambique tanzania randomized receive either three doses iptpmq 15 mgkg placebo given least one month apart received ctxp llitn iptpmq associated reduced rates maternal parasitemia risk ratio rr 047 95 ci 027082 p0008 placental malaria rr 052 95 ci 029090 p0021 reduced incidence nonobstetric hospital admissions rr 059 95 ci 037095 p0031 intention treat itt analysis differences prevalence adverse pregnancy outcomes groups drug tolerability poorer mq group compared control group 296 referred dizziness 239 vomiting first iptpmq administration hiv viral load delivery higher mq group compared control group p0048 atp analysis frequency perinatal mother child transmission hiv increased women received mq rr 195 95 ci 114333 p0015 main limitation latter finding relates exploratory nature part analysisan effective antimalarial added ctxp llitns hivinfected pregnant women improve malaria prevention well maternal health reduction hospital admissions however mq well tolerated limiting potential iptp indicating need find alternatives better tolerability reduce malaria particularly vulnerable group mq associated increased risk mother child transmission hiv warrants better understanding pharmacological interactions antimalarials antiretroviral drugsclinicaltrialsgov nct 00811421 pan african clinical trials registry pactr 2010020001813440 please see later article editors summary